Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET.

Vogel S, Chatterjee M, Metzger K, Borst O, Geisler T, Seizer P, Müller I, Mack A, Schumann S, Bühring HJ, Lang F, Sorg RV, Langer H, Gawaz M.

J Biol Chem. 2014 Apr 18;289(16):11068-82. doi: 10.1074/jbc.M113.530287. Epub 2014 Feb 24.

2.

Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell death.

Vogel S, Börger V, Peters C, Förster M, Liebfried P, Metzger K, Meisel R, Däubener W, Trapp T, Fischer JC, Gawaz M, Sorg RV.

Cell Death Differ. 2015 Jul;22(7):1219-30. doi: 10.1038/cdd.2014.225. Epub 2015 Jan 9.

3.

Hepatocyte growth factor-mediated attraction of mesenchymal stem cells for apoptotic neuronal and cardiomyocytic cells.

Vogel S, Trapp T, Börger V, Peters C, Lakbir D, Dilloo D, Sorg RV.

Cell Mol Life Sci. 2010 Jan;67(2):295-303. doi: 10.1007/s00018-009-0183-3. Epub 2009 Nov 3.

PMID:
19888551
4.

Mesenchymal stem cell secreted platelet derived growth factor exerts a pro-migratory effect on resident Cardiac Atrial appendage Stem Cells.

Windmolders S, De Boeck A, Koninckx R, Daniëls A, De Wever O, Bracke M, Hendrikx M, Hensen K, Rummens JL.

J Mol Cell Cardiol. 2014 Jan;66:177-88. doi: 10.1016/j.yjmcc.2013.11.016. Epub 2013 Dec 8.

PMID:
24326234
5.

A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats.

Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H, Nakamura T.

Cardiovasc Res. 2001 Jul;51(1):41-50.

PMID:
11399246
6.

The HMGB1-TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis.

Ding HS, Yang J, Chen P, Yang J, Bo SQ, Ding JW, Yu QQ.

Gene. 2013 Sep 15;527(1):389-93. doi: 10.1016/j.gene.2013.05.041. Epub 2013 May 30.

PMID:
23727604
7.

VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart.

Tang JM, Wang JN, Zhang L, Zheng F, Yang JY, Kong X, Guo LY, Chen L, Huang YZ, Wan Y, Chen SY.

Cardiovasc Res. 2011 Aug 1;91(3):402-11. doi: 10.1093/cvr/cvr053. Epub 2011 Feb 22.

8.

Migration of mesenchymal stem cells towards glioblastoma cells depends on hepatocyte-growth factor and is enhanced by aminolaevulinic acid-mediated photodynamic treatment.

Vogel S, Peters C, Etminan N, Börger V, Schimanski A, Sabel MC, Sorg RV.

Biochem Biophys Res Commun. 2013 Feb 15;431(3):428-32. doi: 10.1016/j.bbrc.2012.12.153. Epub 2013 Jan 16.

PMID:
23333382
9.

Necroptosis Induced by Ad-HGF Activates Endogenous C-Kit+ Cardiac Stem Cells and Promotes Cardiomyocyte Proliferation and Angiogenesis in the Infarcted Aged Heart.

Liu J, Wu P, Wang H, Wang Y, Du Y, Cheng W, Xu Z, Zhou N, Wang L, Yang Z.

Cell Physiol Biochem. 2016;40(5):847-860. Epub 2016 Dec 7.

10.

Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction.

Dong F, Harvey J, Finan A, Weber K, Agarwal U, Penn MS.

Circulation. 2012 Jul 17;126(3):314-24. doi: 10.1161/CIRCULATIONAHA.111.082453. Epub 2012 Jun 9.

11.

Mesenchymal stem cells overexpressing GCP-2 improve heart function through enhanced angiogenic properties in a myocardial infarction model.

Kim SW, Lee DW, Yu LH, Zhang HZ, Kim CE, Kim JM, Park TH, Cha KS, Seo SY, Roh MS, Lee KC, Jung JS, Kim MH.

Cardiovasc Res. 2012 Sep 1;95(4):495-506. doi: 10.1093/cvr/cvs224. Epub 2012 Aug 10.

PMID:
22886775
12.

[Influence of hepatocyte growth factor on biological characteristics of bone marrow-derived mesenchymal stem cells].

Liu HJ, Duan HF, Lu ZZ, Wang H, Zhang QW, Wu ZZ, Wang LS.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Dec;13(6):1044-8. Chinese.

PMID:
16403277
13.

Cellular and molecular mechanisms of HGF/Met in the cardiovascular system.

Gallo S, Sala V, Gatti S, Crepaldi T.

Clin Sci (Lond). 2015 Dec;129(12):1173-93. doi: 10.1042/CS20150502. Review.

PMID:
26561593
14.
15.

Thrombomodulin's lectin-like domain reduces myocardial damage by interfering with HMGB1-mediated TLR2 signalling.

Herzog C, Lorenz A, Gillmann HJ, Chowdhury A, Larmann J, Harendza T, Echtermeyer F, Müller M, Schmitz M, Stypmann J, Seidler DG, Damm M, Stehr SN, Koch T, Wollert KC, Conway EM, Theilmeier G.

Cardiovasc Res. 2014 Mar 1;101(3):400-10. doi: 10.1093/cvr/cvt275. Epub 2013 Dec 9.

PMID:
24323314
16.

High-mobility group box 1 (HMGB1) impaired cardiac excitation-contraction coupling by enhancing the sarcoplasmic reticulum (SR) Ca(2+) leak through TLR4-ROS signaling in cardiomyocytes.

Zhang C, Mo M, Ding W, Liu W, Yan D, Deng J, Luo X, Liu J.

J Mol Cell Cardiol. 2014 Sep;74:260-73. doi: 10.1016/j.yjmcc.2014.06.003. Epub 2014 Jun 14.

PMID:
24937603
17.

High mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes progression of gastric cancer.

Yue Y, Zhou T, Gao Y, Zhang Z, Li L, Liu L, Shi W, Su L, Cheng B.

Tumour Biol. 2017 Mar;39(3):1010428317694312. doi: 10.1177/1010428317694312.

PMID:
28347236
18.

Combined administration of mesenchymal stem cells overexpressing IGF-1 and HGF enhances neovascularization but moderately improves cardiac regeneration in a porcine model.

Gómez-Mauricio G, Moscoso I, Martín-Cancho MF, Crisóstomo V, Prat-Vidal C, Báez-Díaz C, Sánchez-Margallo FM, Bernad A.

Stem Cell Res Ther. 2016 Jul 16;7(1):94. doi: 10.1186/s13287-016-0350-z.

19.

Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction.

Deuse T, Peter C, Fedak PW, Doyle T, Reichenspurner H, Zimmermann WH, Eschenhagen T, Stein W, Wu JC, Robbins RC, Schrepfer S.

Circulation. 2009 Sep 15;120(11 Suppl):S247-54. doi: 10.1161/CIRCULATIONAHA.108.843680.

20.

Platelet-derived HMGB1 is a critical mediator of thrombosis.

Vogel S, Bodenstein R, Chen Q, Feil S, Feil R, Rheinlaender J, Schäffer TE, Bohn E, Frick JS, Borst O, Münzer P, Walker B, Markel J, Csanyi G, Pagano PJ, Loughran P, Jessup ME, Watkins SC, Bullock GC, Sperry JL, Zuckerbraun BS, Billiar TR, Lotze MT, Gawaz M, Neal MD.

J Clin Invest. 2015 Dec;125(12):4638-54. doi: 10.1172/JCI81660. Epub 2015 Nov 9.

Supplemental Content

Support Center